DK3350341T3 - Fremgangsmåder til diagnosticering og evaluering af non-alkoholisk steatohepatitis - Google Patents
Fremgangsmåder til diagnosticering og evaluering af non-alkoholisk steatohepatitis Download PDFInfo
- Publication number
- DK3350341T3 DK3350341T3 DK16769923.0T DK16769923T DK3350341T3 DK 3350341 T3 DK3350341 T3 DK 3350341T3 DK 16769923 T DK16769923 T DK 16769923T DK 3350341 T3 DK3350341 T3 DK 3350341T3
- Authority
- DK
- Denmark
- Prior art keywords
- diagnosis
- evaluation
- methods
- alcoholic steatohepatitis
- steatohepatitis
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/66—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood sugars, e.g. galactose
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
- G01N33/721—Haemoglobin
- G01N33/723—Glycosylated haemoglobin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/81—Protease inhibitors
- G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/08—Hepato-biliairy disorders other than hepatitis
- G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Analytical Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15306412 | 2015-09-14 | ||
PCT/EP2016/071727 WO2017046181A1 (en) | 2015-09-14 | 2016-09-14 | Methods for diagnosing and evaluating non-alcoholic steatohepatitis |
Publications (1)
Publication Number | Publication Date |
---|---|
DK3350341T3 true DK3350341T3 (da) | 2021-09-27 |
Family
ID=54199140
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK16769923.0T DK3350341T3 (da) | 2015-09-14 | 2016-09-14 | Fremgangsmåder til diagnosticering og evaluering af non-alkoholisk steatohepatitis |
DK20169118.5T DK3712279T3 (da) | 2015-09-14 | 2016-09-14 | Fremgangsmåder til diagnosticering og evaluering af non-alkoholisk steatohepatitis |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK20169118.5T DK3712279T3 (da) | 2015-09-14 | 2016-09-14 | Fremgangsmåder til diagnosticering og evaluering af non-alkoholisk steatohepatitis |
Country Status (19)
Country | Link |
---|---|
US (2) | US11371098B2 (da) |
EP (2) | EP3712279B1 (da) |
JP (2) | JP6947721B2 (da) |
KR (1) | KR20180049098A (da) |
CN (1) | CN108138232B (da) |
AU (1) | AU2016323380B2 (da) |
CA (1) | CA2997336A1 (da) |
DK (2) | DK3350341T3 (da) |
EA (1) | EA201890724A1 (da) |
ES (1) | ES2891347T3 (da) |
FI (1) | FI3712279T3 (da) |
HK (1) | HK1255351A1 (da) |
HU (1) | HUE056299T2 (da) |
IL (1) | IL257680B2 (da) |
MX (1) | MX2018003077A (da) |
PH (1) | PH12018500513A1 (da) |
PT (1) | PT3350341T (da) |
WO (1) | WO2017046181A1 (da) |
ZA (1) | ZA201801630B (da) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG11201505515XA (en) | 2012-01-27 | 2015-09-29 | Univ Leland Stanford Junior | Methods for profiling and quantitating cell-free rna |
SG11201808192RA (en) * | 2016-03-30 | 2018-10-30 | Genfit | Non-invasive diagnostic of non-alcoholic steatohepatitis |
MX2020002004A (es) * | 2017-08-25 | 2020-10-05 | Genfit | Diagnostico no invasivo de esteatosis hepatica no alcoholica, esteatohepatitis no alcoholica y/o fibrosis hepatica. |
SG11202001379WA (en) | 2017-09-08 | 2020-03-30 | Bristol Myers Squibb Co | Modified fibroblast growth factor 21 (fgf-21) for use in methods for treating nonalcoholic steatohepatitis (nash) |
WO2019053235A1 (en) | 2017-09-15 | 2019-03-21 | Genfit | NON-INVASIVE DIAGNOSIS OF NON ALCOHOLIC LIVER DISEASES, NON ALCOHOLIC STHEATHEPATITIS AND / OR HEPATIC FIBROSIS |
CN111065748B (zh) | 2017-09-18 | 2024-04-09 | 基恩菲特公司 | 非酒精性脂肪性肝病、非酒精性脂肪性肝炎和/或肝纤维化的非侵入性诊断 |
EP3546597A1 (en) | 2018-03-28 | 2019-10-02 | Sanofi | Biomarker panel for nafld/nash |
GB2612911B (en) | 2019-02-14 | 2023-11-22 | Mirvie Inc | Methods and systems for determining a pregnancy-related state of a subject |
AU2020236904A1 (en) | 2019-03-13 | 2021-08-19 | Genfit | Diagnosis of non-alcoholic steatohepatitis |
CN110143890B (zh) * | 2019-06-12 | 2020-12-22 | 天津科技大学 | 一种查尔酮衍生物和合成方法及其在制备抗非酒精性脂肪肝炎药物中的应用 |
KR20210010100A (ko) | 2019-07-19 | 2021-01-27 | 고려대학교 산학협력단 | 체질량지수와 자기공명영상을 이용한 비알코올성 지방간 질환 진단방법 |
CN110484605B (zh) * | 2019-09-23 | 2020-07-28 | 中国人民解放军陆军军医大学第一附属医院 | 一种活细胞原位检测microRNA-34的基因及其制备方法和应用 |
CN110578003A (zh) * | 2019-10-22 | 2019-12-17 | 安徽医科大学第二附属医院 | miR-200a在制备肝癌诊断治疗试剂盒及在制备抗肿瘤药物中的应用 |
KR102341336B1 (ko) * | 2019-11-20 | 2021-12-21 | 숙명여자대학교산학협력단 | 만성간질환의 예후 예측용 바이오마커 조성물 |
KR20230097095A (ko) * | 2020-10-30 | 2023-06-30 | 더 제너럴 하스피탈 코포레이션 | 간 질환의 평가를 위한 키트, 시약 및 방법 |
US20240002939A1 (en) * | 2020-10-30 | 2024-01-04 | Genfit | Methods of diagnostic of liver fibrosis |
WO2024038901A1 (ja) * | 2022-08-17 | 2024-02-22 | 公益財団法人東京都医学総合研究所 | 肝疾患非侵襲性バイオマーカー及びこれを用いた肝疾患の検出 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2621838T3 (es) * | 2008-11-18 | 2017-07-05 | Universite D'angers | Método in vitro no invasivo para la cuantificación de lesiones hepáticas |
ES2681794T3 (es) * | 2009-11-26 | 2018-09-17 | Genfit | Uso de derivados de 1,3-difenilprop-2-en-1-ona para tratar trastornos hepáticos |
EP2776590B1 (en) * | 2011-11-07 | 2016-10-26 | Roche Innovation Center Copenhagen A/S | Prognostic method for checking efficacy of micro rna-122 inhibitors in hcv+ patients |
WO2013068348A1 (en) | 2011-11-07 | 2013-05-16 | Santaris Pharma A/S | Lna oligomers for improvement in hepatic function |
EP2818549A4 (en) | 2012-02-23 | 2015-09-02 | Sumitomo Bakelite Co | METHOD FOR CLASSIFYING BODY FLUID SAMPLE OF TEST |
EP2684513A1 (en) * | 2012-07-13 | 2014-01-15 | Universite D'angers | Method for providing reliable non-invasive diagnostic tests |
WO2014049131A1 (en) * | 2012-09-28 | 2014-04-03 | Université d'Angers | Accurate blood test for the non-invasive diagnosis of non-alcoholic steatohepatitis |
KR20140147920A (ko) * | 2013-06-19 | 2014-12-31 | 가톨릭대학교 산학협력단 | 비알코올성 지방간염 감별용 바이오마커 miR-34a |
CN104293908A (zh) * | 2014-06-18 | 2015-01-21 | 镇江市第三人民医院 | 用于检测非酒精性脂肪肝的血清miRNA标志物组合及应用 |
-
2016
- 2016-09-14 DK DK16769923.0T patent/DK3350341T3/da active
- 2016-09-14 EP EP20169118.5A patent/EP3712279B1/en active Active
- 2016-09-14 DK DK20169118.5T patent/DK3712279T3/da active
- 2016-09-14 WO PCT/EP2016/071727 patent/WO2017046181A1/en active Application Filing
- 2016-09-14 ES ES16769923T patent/ES2891347T3/es active Active
- 2016-09-14 PT PT167699230T patent/PT3350341T/pt unknown
- 2016-09-14 HU HUE16769923A patent/HUE056299T2/hu unknown
- 2016-09-14 FI FIEP20169118.5T patent/FI3712279T3/fi active
- 2016-09-14 EP EP16769923.0A patent/EP3350341B1/en active Active
- 2016-09-14 MX MX2018003077A patent/MX2018003077A/es unknown
- 2016-09-14 CN CN201680053197.2A patent/CN108138232B/zh active Active
- 2016-09-14 JP JP2018513289A patent/JP6947721B2/ja active Active
- 2016-09-14 CA CA2997336A patent/CA2997336A1/en active Pending
- 2016-09-14 KR KR1020187010656A patent/KR20180049098A/ko not_active Application Discontinuation
- 2016-09-14 US US15/759,484 patent/US11371098B2/en active Active
- 2016-09-14 IL IL257680A patent/IL257680B2/en unknown
- 2016-09-14 EA EA201890724A patent/EA201890724A1/ru unknown
- 2016-09-14 AU AU2016323380A patent/AU2016323380B2/en active Active
-
2018
- 2018-03-08 PH PH12018500513A patent/PH12018500513A1/en unknown
- 2018-03-09 ZA ZA2018/01630A patent/ZA201801630B/en unknown
- 2018-11-13 HK HK18114490.6A patent/HK1255351A1/zh unknown
-
2021
- 2021-06-01 JP JP2021092441A patent/JP7274523B2/ja active Active
-
2022
- 2022-06-24 US US17/849,161 patent/US20220411874A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20220411874A1 (en) | 2022-12-29 |
JP6947721B2 (ja) | 2021-10-13 |
AU2016323380B2 (en) | 2023-01-05 |
HUE056299T2 (hu) | 2022-02-28 |
ZA201801630B (en) | 2019-01-30 |
EP3350341B1 (en) | 2021-08-11 |
EP3712279B1 (en) | 2024-03-20 |
EP3712279A1 (en) | 2020-09-23 |
MX2018003077A (es) | 2018-05-28 |
DK3712279T3 (da) | 2024-06-03 |
KR20180049098A (ko) | 2018-05-10 |
JP2021144048A (ja) | 2021-09-24 |
IL257680A (en) | 2018-04-30 |
CN108138232B (zh) | 2023-07-18 |
IL257680B2 (en) | 2023-03-01 |
ES2891347T3 (es) | 2022-01-27 |
AU2016323380A1 (en) | 2018-03-29 |
EP3350341A1 (en) | 2018-07-25 |
JP7274523B2 (ja) | 2023-05-16 |
FI3712279T3 (fi) | 2024-05-28 |
US20180265924A1 (en) | 2018-09-20 |
CN108138232A (zh) | 2018-06-08 |
JP2018534542A (ja) | 2018-11-22 |
PT3350341T (pt) | 2021-09-28 |
CA2997336A1 (en) | 2017-03-23 |
PH12018500513A1 (en) | 2018-09-24 |
IL257680B (en) | 2022-11-01 |
HK1255351A1 (zh) | 2019-08-16 |
EA201890724A1 (ru) | 2018-10-31 |
WO2017046181A1 (en) | 2017-03-23 |
US11371098B2 (en) | 2022-06-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK3350341T3 (da) | Fremgangsmåder til diagnosticering og evaluering af non-alkoholisk steatohepatitis | |
DK3295951T3 (da) | Anti-pvrig-antistoffer og fremgangsmåder for anvendelse | |
DK3280441T3 (da) | Anti-sortilin-antistoffer og fremgangsmåder til anvendelse deraf | |
DK3230319T3 (da) | Anti-PD-1-antistoffer og fremgangsmåder til anvendelse deraf | |
DK3303394T3 (da) | Anti-ctla-4-antistoffer og fremgangsmåder til anvendelse deraf | |
DK3317284T3 (da) | Benzoxazepin-oxazolidinonforbindelser og fremgangsmåder til anvendelse | |
DK3126394T3 (da) | Anti-OX40-antistoffer og fremgangsmåder til anvendelse | |
DK3215532T3 (da) | Anti-TIM3-antistoffer og fremgangsmåder til anvendelse | |
DK3356404T3 (da) | Anti-pd1-antistoffer og fremgangsmåder til anvendelse | |
DK3309174T3 (da) | ANTI-PD-L1-antistoffer og diagnostiske anvendelser deraf | |
DK3325669T3 (da) | Sammensætninger og fremgangsmåder til RNA-analyse | |
DK3292149T3 (da) | Aktiverbare anti-cd71-antistoffer og fremgangsmåder til anvendelse deraf | |
DK3234133T3 (da) | Crispr-baserede sammensætninger og fremgangsmåder til anvendelse | |
DK3227336T3 (da) | Anti-CD79b-antistoffer og fremgangsmåder til anvendelse | |
DK3888658T3 (da) | Eif4-a-inhiberende forbindelser og fremgangsmåder relateret dertil | |
DK3316909T3 (da) | Anti-ntb-a-antistoffer og relaterede sammensætninger og fremgangsmåder | |
DK3148579T3 (da) | Anti-gitr antistoffer og fremgangsmåder til anvendelse deraf | |
DK3182901T3 (da) | System og fremgangsmåde til ikke-invasiv analyse af kropsfluider | |
DK3102673T3 (da) | Fremgangsmåder og sammensætninger til behandling af beta-talassæmi | |
DK3486604T3 (da) | Indretning til intraoral tredimensionel måling, fremgangsmåde til intraoral tredimensionel måling og fremgangsmåde til visning af resultat af intraoral tredimensionel måling | |
DK3215147T3 (da) | Neurodæmpende norketamin-forbindelser og fremgangsmåder | |
DK3144001T3 (da) | Sammensætninger af selenoorganiske forbindelser og fremgangsmåder til anvendelse deraf | |
DK3430038T3 (da) | Sammensætninger og fremgangsmåder til cd20-immunterapi | |
DK3116911T3 (da) | Anti-mcam-antistoffer og tilhørende fremgangsmåder til anvendelse | |
DK3209696T3 (da) | Fremgangsmåder og sammensætninger til diagnosticering og behandling af glioblastom |